Evidence map›Paper›PMID 40770726›Full record

ArticleJournal of nanobiotechnology2025

Novel multifunctional targeted nanozyme as an ultrasound contrast agent for real-time monitoring and treatment of congenital hydronephrosis renal fibrosis.

Qian Zhao, Di Zhang, Keyan Chen, Feifei Sun, Yixin Chen

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qian Zhao *Department of Pediatric Urology, Shengjing Hospital of China Medical University, Shenyang, 110004, Liaoning, China.
Di Zhang *Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, 110004, Liaoning, China.
Keyan Chen *Laboratory Animal Science of China Medical University, Shenyang, Liaoning, 110122, China.
Feifei SunDepartment of Ultrasound, Shengjing Hospital of China Medical University, 36#,Sanhao Street, Heping District, Shenyang, Liaoning, 110004, China. sffecho0120@163.com.
Yixin ChenDepartment of Ultrasound, Shengjing Hospital of China Medical University, 36#,Sanhao Street, Heping District, Shenyang, Liaoning, 110004, China. 20192107@cmu.edu.cn.

Funding

Basic scientific research project of Liaoning Provincial Department of Education LJKMZ20221180National Natural Science Foundation of China 82371722Shenyang Science and Technology Plan. Public Health R&D Special Project 21-173-9-67Study and formulation of early screening and diagnosis criteria for structural birth defects 2021YFC2701003
6 · The paper itself

Abstract

backgroundCongenital Hydronephrosis (CH) is a common pediatric disorder that often leads to renal fibrosis (RF), significantly impairing kidney function. Oxidative stress (OS) plays a central role in the pathogenesis of RF. Current treatments lack effective monitoring and targeted therapies for CH, thus highlighting the need for innovative diagnostic and therapeutic approaches. This study explores a novel multifunctional nanozyme, pH-responsive PEG-SH and imidazole-modified gold nanoparticles (PMIZ-AuNPs), for both real-time ultrasound monitoring and treatment of CH-induced RF.

resultsWe designed a pH-responsive nanozyme, consisting of PEG-SH and PMIZ-AuNPs. This nanozyme exhibits enhanced ultrasound imaging properties and dual catalytic activities, including superoxide dismutase (SOD) and catalase (CAT), under acidic conditions. In a unilateral ureteral obstruction (UUO) mouse model, PMIZ-AuNPs accumulated at injury sites, enhancing ultrasound signal intensity and improving RF. Protein sequencing and bioinformatics analysis identified C9 as a critical gene involved in RF. Further experiments showed that PMIZ-AuNPs reduced C9 expression by inhibiting OS and modulated the TGF-β signaling pathway, leading to significant attenuation of RF in both in vitro and in vivo models.

conclusionPMIZ-AuNPs demonstrate significant potential as a multifunctional tool for the diagnosis and treatment of CH-induced RF. By targeting oxidative stress and modulating C9 expression, PMIZ-AuNPs improve renal function and offer a promising strategy for the clinical management of CH.

Indexed as

Contrast MediaHydronephrosisMetal NanoparticlesAnimalsDisease Models, AnimalFibrosisGoldHumansHydrogen-Ion ConcentrationImidazolesKidneyMaleMiceMice, Inbred C57BLOxidative StressSuperoxide DismutaseContrast MediaGoldimidazoleImidazolesSuperoxide DismutaseCongenital hydronephrosisNanozymeOxidative stressRenal fibrosisUltrasound contrast agent

Identifiers

PMID40770726
PMCPMC12326633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.